{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:26:55Z","timestamp":1769095615219,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Science and Technology Support Program, China","award":["21S11909700,21S11903200"],"award-info":[{"award-number":["21S11909700,21S11903200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00705-024-06082-8","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:01:40Z","timestamp":1720674100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice"],"prefix":"10.1007","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-9008","authenticated-orcid":false,"given":"Jian","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feixia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Song","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"20","key":"6082_CR1","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","volume":"368","author":"R Gao","year":"2013","unstructured":"Gao R et al (2013) Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368(20):1888\u20131897","journal-title":"N Engl J Med"},{"issue":"11","key":"6082_CR2","doi-asserted-by":"publisher","first-page":"e1001558","DOI":"10.1371\/journal.pmed.1001558","volume":"10","author":"L Simonsen","year":"2013","unstructured":"Simonsen L et al (2013) Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med 10(11):e1001558","journal-title":"PLoS Med"},{"issue":"2","key":"6082_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jinf.2018.09.009","volume":"78","author":"G Hou","year":"2019","unstructured":"Hou G et al (2019) Hemagglutinin characteristics, changes in pathogenicity, and antigenic variation of highly pathogenic H7N9 avian influenza viruses in China. J Infect 78(2):158\u2013169","journal-title":"J Infect"},{"issue":"1","key":"6082_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/22221751.2018.1560234","volume":"8","author":"L Bao","year":"2019","unstructured":"Bao L et al (2019) Diverse biological characteristics and varied virulence of H7N9 from Wave 5. Emerg Microbes Infect 8(1):94\u2013102","journal-title":"Emerg Microbes Infect"},{"key":"6082_CR5","doi-asserted-by":"crossref","unstructured":"Zhu W (2017) J.Z.Z.L., Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017. Euro Surveill","DOI":"10.2807\/1560-7917.ES.2017.22.19.30533"},{"key":"6082_CR6","doi-asserted-by":"crossref","unstructured":"Manini I et al (2017) Egg-Independent Influenza Vaccines and Vaccine Candidates. Vaccines (Basel), 5(3)","DOI":"10.3390\/vaccines5030018"},{"issue":"5","key":"6082_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","volume":"11","author":"NR Hegde","year":"2015","unstructured":"Hegde NR (2015) Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Hum Vaccin Immunother 11(5):1223\u20131234","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"6082_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1586\/14760584.2015.1039520","volume":"14","author":"I Manini","year":"2015","unstructured":"Manini I et al (2015) Flucelvax (Optaflu) for seasonal influenza. Expert Rev Vaccines 14(6):789\u2013804","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"6082_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/INF.0b013e31824bb179","volume":"31","author":"T Vesikari","year":"2012","unstructured":"Vesikari T et al (2012) Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 31(5):494\u2013500","journal-title":"Pediatr Infect Dis J"},{"issue":"33","key":"6082_CR10","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1016\/j.vaccine.2017.06.044","volume":"35","author":"UI Wu","year":"2017","unstructured":"Wu UI et al (2017) Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I\/II, prospective, randomized, open-label trial. Vaccine 35(33):4099\u20134104","journal-title":"Vaccine"},{"issue":"8","key":"6082_CR11","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3201\/eid2308.170600","volume":"23","author":"C Ke","year":"2017","unstructured":"Ke C et al (2017) Human Infection with Highly Pathogenic Avian Influenza A(H7N9) Virus, China. Emerg Infect Dis 23(8):1332\u20131340","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"6082_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/21645515.2018.1515454","volume":"15","author":"D Zheng","year":"2019","unstructured":"Zheng D et al (2019) Comparative effectiveness of H7N9 vaccines in healthy individuals. Hum Vaccin Immunother 15(1):80\u201390","journal-title":"Hum Vaccin Immunother"},{"key":"6082_CR13","doi-asserted-by":"crossref","unstructured":"Mark J, Mulligan M et al (2014) Serological Responses to an Avian Influenza A\/H7N9 Vaccine Mixed at the Point-of-Use with MF59 Adjuvant. JAMA","DOI":"10.1001\/jama.2014.12854"},{"issue":"11","key":"6082_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/infdis\/jiw414","volume":"214","author":"A Madan","year":"2016","unstructured":"Madan A et al (2016) Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults. J Infect Dis 214(11):1717\u20131727","journal-title":"J Infect Dis"},{"issue":"32","key":"6082_CR15","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1016\/j.vaccine.2015.06.047","volume":"33","author":"KY Chung","year":"2015","unstructured":"Chung KY et al (2015) ISCOMATRIX adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine 33(32):3953\u20133962","journal-title":"Vaccine"},{"issue":"2","key":"6082_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/156802608783378882","volume":"8","author":"DA Johnson","year":"2008","unstructured":"Johnson DA (2008) Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem 8(2):64\u201379","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"6082_CR17","first-page":"2654","volume":"41","author":"K Takayama","year":"1981","unstructured":"Takayama K, Ribi E, Cantrell JL (1981) Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res 41(7):2654\u20132657","journal-title":"Cancer Res"},{"issue":"1","key":"6082_CR18","first-page":"1","volume":"3","author":"E Ribi","year":"1984","unstructured":"Ribi E (1984) Beneficial modification of the endotoxin molecule. J Biol Response Mod 3(1):1\u20139","journal-title":"J Biol Response Mod"},{"key":"6082_CR19","doi-asserted-by":"publisher","first-page":"104502","DOI":"10.1016\/j.phrs.2019.104502","volume":"150","author":"A Hernandez","year":"2019","unstructured":"Hernandez A et al (2019) Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection. Pharmacol Res 150:104502","journal-title":"Pharmacol Res"},{"issue":"12","key":"6082_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00262-001-0241-7","volume":"50","author":"M Satoh","year":"2002","unstructured":"Satoh M et al (2002) Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007, with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity. Cancer Immunol Immunother 50(12):653\u2013662","journal-title":"Cancer Immunol Immunother"},{"key":"6082_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1471-2407-13-172","volume":"13","author":"N Isambert","year":"2013","unstructured":"Isambert N et al (2013) Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer 13:172","journal-title":"BMC Cancer"},{"issue":"10","key":"6082_CR22","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.4049\/jimmunol.2200495","volume":"209","author":"A Gopalakrishnan","year":"2022","unstructured":"Gopalakrishnan A et al (2022) E6020, a TLR4 Agonist Adjuvant, Enhances Both Antibody Titers and Isotype Switching in Response to Immunization with Hapten-Protein Antigens and Is Diminished in Mice with TLR4 Signaling Insufficiency. J Immunol 209(10):1950\u20131959","journal-title":"J Immunol"},{"issue":"2","key":"6082_CR23","doi-asserted-by":"publisher","first-page":"e88979","DOI":"10.1371\/journal.pone.0088979","volume":"9","author":"CH Clegg","year":"2014","unstructured":"Clegg CH et al (2014) GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. PLoS ONE 9(2):e88979","journal-title":"PLoS ONE"},{"key":"6082_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.smim.2018.10.004","volume":"39","author":"SG Reed","year":"2018","unstructured":"Reed SG et al (2018) Correlates of GLA family adjuvants\u2019 activities. Semin Immunol 39:22\u201329","journal-title":"Semin Immunol"},{"issue":"3","key":"6082_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/eji.200939992","volume":"40","author":"A Legat","year":"2010","unstructured":"Legat A et al (2010) CD14-independent responses induced by a synthetic lipid A mimetic. Eur J Immunol 40(3):797\u2013802","journal-title":"Eur J Immunol"},{"key":"6082_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1743-422X-8-42","volume":"8","author":"H Zhang","year":"2011","unstructured":"Zhang H et al (2011) Characterization of an H10N8 influenza virus isolated from Dongting lake wetland. Virol J 8:42","journal-title":"Virol J"},{"issue":"5","key":"6082_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biologicals.2010.04.003","volume":"38","author":"D Onions","year":"2010","unstructured":"Onions D et al (2010) Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 38(5):544\u2013551","journal-title":"Biologicals"},{"issue":"1","key":"6082_CR28","doi-asserted-by":"publisher","first-page":"e30898","DOI":"10.1371\/journal.pone.0030898","volume":"7","author":"N Budimir","year":"2012","unstructured":"Budimir N et al (2012) Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS ONE 7(1):e30898","journal-title":"PLoS ONE"},{"issue":"22","key":"6082_CR29","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.vaccine.2017.03.016","volume":"36","author":"YF Tseng","year":"2018","unstructured":"Tseng YF et al (2018) A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography. Vaccine 36(22):3146\u20133152","journal-title":"Vaccine"},{"issue":"5","key":"6082_CR30","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/bit.21109","volume":"96","author":"B Kalbfuss","year":"2007","unstructured":"Kalbfuss B et al (2007) Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol Bioeng 96(5):932\u2013944","journal-title":"Biotechnol Bioeng"},{"key":"6082_CR31","unstructured":"WHO Recommendations for the production and control of influenza vaccine (inactivated), Annex 3, TRS No 927. p. Publications of the World Health Organization"},{"key":"6082_CR32","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3389\/fimmu.2019.02274","volume":"10","author":"J Luo","year":"2019","unstructured":"Luo J et al (2019) Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant. Front Immunol 10:2274","journal-title":"Front Immunol"},{"issue":"1","key":"6082_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41541-020-0187-4","volume":"5","author":"J de Jonge","year":"2020","unstructured":"de Jonge J et al (2020) H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets. NPJ Vaccines 5(1):38","journal-title":"NPJ Vaccines"},{"issue":"1","key":"6082_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41541-021-00295-7","volume":"6","author":"P Radvak","year":"2021","unstructured":"Radvak P et al (2021) Highly pathogenic avian influenza A\/Guangdong\/17SF003\/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses. NPJ Vaccines 6(1):30","journal-title":"NPJ Vaccines"},{"issue":"1\u20132","key":"6082_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0022-1759(90)90255-T","volume":"135","author":"CR Lambre","year":"1990","unstructured":"Lambre CR et al (1990) Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 135(1\u20132):49\u201357","journal-title":"J Immunol Methods"},{"key":"6082_CR36","first-page":"p901817","volume":"2015","author":"S Chen","year":"2015","unstructured":"Chen S et al (2015) Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope. Biomed Res Int 2015:p901817","journal-title":"Biomed Res Int"},{"key":"6082_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-0716-0346-8_2","volume":"2123","author":"E Spackman","year":"2020","unstructured":"Spackman E, Sitaras I (2020) Hemagglutination Inhib Assay Methods Mol Biol 2123:11\u201328","journal-title":"Hemagglutination Inhib Assay Methods Mol Biol"},{"key":"6082_CR38","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","volume":"69","author":"JJ Skehel","year":"2000","unstructured":"Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69:531\u2013569","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"6082_CR39","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1586\/14760584.2016.1164046","volume":"15","author":"CM Trombetta","year":"2016","unstructured":"Trombetta CM, Montomoli E (2016) Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines 15(8):967\u2013976","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"6082_CR40","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1128\/JCM.00229-11","volume":"49","author":"V Veguilla","year":"2011","unstructured":"Veguilla V et al (2011) Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 49(6):2210\u20132215","journal-title":"J Clin Microbiol"},{"key":"6082_CR41","doi-asserted-by":"crossref","unstructured":"Desheva Y et al (2020) Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines. Antibodies (Basel), 9(2)","DOI":"10.3390\/antib9020020"},{"key":"6082_CR42","doi-asserted-by":"crossref","unstructured":"Krammer F et al (2018) NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? mBio, 9(2)","DOI":"10.1128\/mBio.02332-17"},{"key":"6082_CR43","doi-asserted-by":"crossref","unstructured":"Wang Y et al (2020) L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation. J Virol, 94(20)","DOI":"10.1128\/JVI.00667-20"},{"issue":"2","key":"6082_CR44","doi-asserted-by":"publisher","first-page":"e0149149","DOI":"10.1371\/journal.pone.0149149","volume":"11","author":"E Alvarado-Facundo","year":"2016","unstructured":"Alvarado-Facundo E et al (2016) Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies. PLoS ONE 11(2):e0149149","journal-title":"PLoS ONE"},{"issue":"234","key":"6082_CR45","doi-asserted-by":"publisher","first-page":"234ra55","DOI":"10.1126\/scitranslmed.3008761","volume":"6","author":"SA Bart","year":"2014","unstructured":"Bart SA et al (2014) A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults. Sci Transl Med 6(234):234ra55","journal-title":"Sci Transl Med"},{"issue":"47","key":"6082_CR46","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1016\/j.vaccine.2019.03.024","volume":"37","author":"TT Tzeng","year":"2019","unstructured":"Tzeng TT et al (2019) The stability and immunogenicity of inactivated MDCK cell-derived influenza H7N9 viruses. Vaccine 37(47):7117\u20137122","journal-title":"Vaccine"},{"issue":"5","key":"6082_CR47","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1128\/IAI.73.5.3044-3052.2005","volume":"73","author":"CW Cluff","year":"2005","unstructured":"Cluff CW et al (2005) Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 73(5):3044\u20133052","journal-title":"Infect Immun"},{"issue":"7","key":"6082_CR48","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","volume":"4","author":"JR Baldridge","year":"2004","unstructured":"Baldridge JR et al (2004) Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4(7):1129\u20131138","journal-title":"Expert Opin Biol Ther"},{"key":"6082_CR49","doi-asserted-by":"publisher","first-page":"104776","DOI":"10.1016\/j.antiviral.2020.104776","volume":"177","author":"J Dong","year":"2020","unstructured":"Dong J et al (2020) Evaluation of the immune response of a H7N9 candidate vaccine virus derived from the fifth wave A\/Guangdong\/17SF003\/2016. Antiviral Res 177:104776","journal-title":"Antiviral Res"},{"issue":"4","key":"6082_CR50","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/infdis\/jiv099","volume":"212","author":"SS Wong","year":"2015","unstructured":"Wong SS et al (2015) Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets. J Infect Dis 212(4):542\u2013551","journal-title":"J Infect Dis"},{"issue":"2","key":"6082_CR51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11262-021-01827-y","volume":"57","author":"L Liu","year":"2021","unstructured":"Liu L et al (2021) The effect of single amino acid substitution at position 220 in the hemagglutinin glycoprotein on avian influenza H7N9 candidate vaccine virus. Virus Genes 57(2):164\u2013171","journal-title":"Virus Genes"},{"key":"6082_CR52","doi-asserted-by":"crossref","unstructured":"Gao F et al (2022) AddaVax-Adjuvanted H5N8 Inactivated Vaccine Induces Robust Humoral Immune Response against Different Clades of H5 Viruses. Vaccines (Basel), 10(10)","DOI":"10.3390\/vaccines10101683"},{"key":"6082_CR53","doi-asserted-by":"crossref","unstructured":"Walz L et al (2018) Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype. J Virol, 92(17)","DOI":"10.1128\/JVI.01006-18"},{"issue":"2","key":"6082_CR54","doi-asserted-by":"publisher","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","volume":"6","author":"TJ Wohlbold","year":"2015","unstructured":"Wohlbold TJ et al (2015) Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 6(2):e02556","journal-title":"mBio"},{"issue":"28","key":"6082_CR55","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1016\/S0264-410X(00)00149-3","volume":"18","author":"Z Chen","year":"2000","unstructured":"Chen Z et al (2000) Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18(28):3214\u20133222","journal-title":"Vaccine"},{"key":"6082_CR56","doi-asserted-by":"crossref","unstructured":"Wan H et al (2018) Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection. J Virol, 92(4)","DOI":"10.1128\/JVI.01588-17"},{"issue":"2","key":"6082_CR57","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000488631","volume":"46","author":"XX Wu","year":"2018","unstructured":"Wu XX et al (2018) The Protective Effects of the A\/ZJU01\/ PR8\/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB\/c Mice. Cell Physiol Biochem 46(2):633\u2013643","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"6082_CR58","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1128\/iai.38.2.530-535.1982","volume":"38","author":"BL Lu","year":"1982","unstructured":"Lu BL, Webster RG, Hinshaw VS (1982) Failure to detect hemagglutination-inhibiting antibodies with intact avian influenza virions. Infect Immun 38(2):530\u2013535","journal-title":"Infect Immun"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-024-06082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-024-06082-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-024-06082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T16:04:22Z","timestamp":1724083462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-024-06082-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["6082"],"URL":"https:\/\/doi.org\/10.1007\/s00705-024-06082-8","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for the animal study (protocol number 2021007) was approved by the laboratory animal management committee and the laboratory animal ethics and welfare protection group of Shanghai Institute of Biological Products. All animal procedures were carried out in accordance with the animal ethics guidelines of the Chinese National Health and Medical Research Council (NHMRC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"163"}}